Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2021 | Optimizing blinatumomab for B-ALL

Rachel Rau • 31 Aug 2021
SOHO 2021
Acute Lymphoblastic Leukemia General Leukemia Antibodies Blinatumomab
AALL1731

Rachel Rau, MD, of Baylor College of Medicine, Houston, TX, discusses the optimal use of blinatumomab for the treatment of B-cell acute lymphoblastic leukemia (B-ALL), commenting on how it could be used to achieve undetectable measurable residual disease (MRD). Dr Rau also talks on the Phase III AALL1731 trial (NCT03914625) currently investigating blinatumomab in combination with chemotherapy for newly diagnosed (B-ALL). This interview took place during the ninth annual meeting of the Society of Hematologic Oncology (SOHO 2021) congress.

Disclosures

Rachel Rau, MD, has participated in consultancy work with Jazz and Servier.

More from Rachel Rau

Updates on BiTEs for B-ALL
4:24
Updates on BiTEs for B-ALL
Rachel Rau • 31 Aug 2021
The importance of optimizing treatment of B-ALL at induction
1:33
The importance of optimizing treatment of B-ALL at induction
Rachel Rau • 31 Aug 2021
B-ALL patient selection for treatment with blinatumomab
3:04
B-ALL patient selection for treatment with blinatumomab
Rachel Rau • 31 Aug 2021

Related Videos

Addressing changes to genomic prognostic markers in CLL beyond the chemotherapy era
4:04
Addressing changes to genomic prognostic markers in CLL beyond the chemotherapy era
Anna Schuh • 16 Oct 2026
Understanding the CLL genome: current knowledge and remaining gaps
3:39
Understanding the CLL genome: current knowledge and remaining gaps
Anna Schuh • 16 Oct 2026
How is frontline fixed-duration acalabrutinib plus venetoclax shaping treatment decisions in CLL?
2:00
How is frontline fixed-duration acalabrutinib plus venetoclax shaping treatment decisions in CLL?
Alexey Danilov • 16 Oct 2026
Autoimmune cytopenias in patients with CLL on venetoclax-based therapy: outcomes from an ERIC study
3:39
Autoimmune cytopenias in patients with CLL on venetoclax-based therapy: outcomes from an ERIC study
Marta Coscia • 16 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals